Jun-Hui Guo 1 , Yuan-Yuan Wang 2 , Jiang-Wei Zhang 2 , Pei-Min Liu 2 , Yan-Jun Hao 2 , Hai-Rui Duan 2 Show Affiliations »
Abstract
BACKGROUND: Apatinib is a small-molecule multitargeted tyrosine kinase inhibitor. Apatinib has demonstrated encouraging antitumor activities. This study aimed to observe the efficacy and safety of apatinib for the treatment of multiple brain micrometastases. CASE SUMMARY: We report two patients with multiple brain micrometastases after failure of second-line treatment. Both patients had extracerebral metastases. When the patients took 250 mg/d apatinib orally, the intracerebral lesions disappeared. The extracerebral lesions were partially alleviated. Both patients had a progression-free survival of more than 12 mo and were still stable. The safety was good. The main adverse events (AEs) were mild hypertension and proteinuria, which could be controlled. CONCLUSION: Apatinib has clear efficacy and good tolerance in patients with multiple brain micrometastases after failure of second-line treatment. ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
BACKGROUND: Apatinib is a small-molecule multitargeted tyrosine kinase inhibitor. Apatinib has demonstrated encouraging antitumor activities. This study aimed to observe the efficacy and safety of apatinib for the treatment of multiple brain micrometastases. CASE SUMMARY: We report two patients with multiple brain micrometastases after failure of second-line treatment. Both patients had extracerebral metastases . When the patients took 250 mg/d apatinib orally, the intracerebral lesions disappeared. The extracerebral lesions were partially alleviated. Both patients had a progression-free survival of more than 12 mo and were still stable. The safety was good. The main adverse events (AEs) were mild hypertension and proteinuria , which could be controlled. CONCLUSION: Apatinib has clear efficacy and good tolerance in patients with multiple brain micrometastases after failure of second-line treatment. ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Entities: Chemical
Disease
Species
Keywords:
Apatinib; Brain micrometastases; Cervical adenocarcinoma; Esophageal squamous cell carcinoma; Tyrosine kinase inhibitor; Vascular endothelial growth factor
Year: 2020
PMID： 32337210 PMCID： PMC7176611 DOI： 10.12998/wjcc.v8.i7.1326
Source DB: PubMed Journal: World J Clin Cases ISSN： 2307-8960 Impact factor: 1.337